Figure 1. Participant Flow in a Trial of Anticoagulation for Venous Thromboembolism in Adults With Cancer.

Oncologists in the Alliance for Clinical Trials in Oncology research network screened their ambulatory patients for adults with a new diagnosis of venous thromboembolism and either (1) an advanced solid tumor, lymphoma, multiple myeloma, or chronic lymphocytic leukemia or (2) an early-stage cancer of one of these same types diagnosed within 12 months of enrollment. Screening logs were not mandatory, so the exact number of screened patients was not captured.

^aSee eFigure 1 in Supplement 2 for participant flow in the preference cohort.

^bPermuted block randomization with varying block sizes was used. No stratification factors were considered at randomization.

^cOf those who did not receive their randomized treatment, 2 received enoxaparin, 1 received fondaparinux, and 2 did not receive any treatment.

^dPatients randomized to receive low-molecular-weight heparin could transition to warfarin with a target international normalized ratio of 2 to 3.

^eOf those who did not receive their randomized treatment, 12 received apixaban, 6 received rivaroxaban, and 10 did not receive any treatment.